68ganota-anti-her2 vhh1
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 24, 2017 (NCT03331601)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Erb-b2 Receptor Tyrosine Kinases · Phase 2
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Salivary Gland Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03924466 | Phase 2 | Apr 1, 2019 | Free University of Brussels, Government of Belgium, Kom Op Tegen Kanker |
| NCT03331601 | Phase 2 | Feb 24, 2017 | Free University of Brussels |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Brussels | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Government of Belgium | Government | 1 | 0 | 1 | 2019 |
| Kom Op Tegen Kanker | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1